RAMP1 and Photophobia: Olcegepant inhibits TNC activity in response to stimulation of the dural vasculature [77, 78], despite having had no apparent effect on trigeminal ganglion activation [77], whereas its administration direct into the CNS blocks CGRP induced photophobia [79] in receptor activity modifying protein 1 (RAMP1) overexpressing mice and inhibits trigeminovascular nociceptive responses at the level of the TNC [78], periaqueductal gray [80], and thalamus [49].